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High throughput screeningM2, Mannose-6-P→ Mannose-1-P) deﬁciency is the most frequent glycosylation
disorder affecting the N-glycosylation pathway. There is no therapy for the hundreds of patients who suffer
from this disorder. This review describes previous attempts at therapeutic interventions and introduces
perspectives emerging from the drawing boards. Two approaches aim to increase Mannose-1-P: small
membrane permeable molecules that increase the availability or/and metabolic ﬂux of precursors into the
impaired glycosylation pathway; and, phosphomannomutase enhancement and/or replacement therapy.
Glycosylation-deﬁcient cell and animal models are needed to determine which individual or combined
approaches improve glycosylation and may be suitable for preclinical evaluation.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionInherited deﬁciency of phosphomannomutase (PMM2) causes a
human glycosylation disorder previously known as Congenital
Disorder of Glycosylation Ia (CDG-Ia) [1]. Pediatric patients have a
broad and variable clinical picture that affects nearly all systems
leading to failure to thrive, hypotonia, variable developmental delay,
ataxia, dysmorphia, skeletal abnormalities, coagulopathy with up to
20% mortality in the ﬁrst 5 years due to organ failure and/or severe
infections [2–5]. Later on they show mental retardation, stroke like
episodes, and retinitis pigmentosa. Adults are usually wheelchair
bound with peripheral neuropathy and stable mental retardation. The
spectrum is broad and recently a considerable number of very mild
patients have been reported [6–10]. There is no therapy for N600
identiﬁed patients; many more patients probably remain undetected.
Scores of mutations have been identiﬁed in PMM2-deﬁcient patients.
Some of these patients have up to 25% normal enzymatic activity,
while heterozygous parents with 50% activity are asymptomatic [9].
This surprisingly high threshold raises the question: how much
enzymatic activity is required to prevent pathology? Since no precise
genotype-phenotype correlation is seen [11], an ensemble of other
unidentiﬁed genes must play important roles. However, patients with
high residual activity tend to have milder phenotypes [11,12]. While
developmental defects that occur in utero cannot be reversed, even a
small improvement in the effective enzymatic activity might reducell rights reserved.the daily medical burden on patients and their families. This hope
makes the pursuit of a therapy worthwhile.
The purpose of this article is to review previous attempts at
therapy for PMM2-deﬁcient patients and to present the rationale for
the development of new ones.
2. Metabolic pathways
PMM2 is an essential gene and its complete loss is lethal in yeast,
mice and presumably humans [13,14]. PMM1 is a homolog of PMM2
[15], and catalyzes the same reaction, but it does not appear to
substitute for loss of PMM2 in mice [16]. PMM1 ablation in mice
produces no obvious pathology or phenotype [16]. Recent studies
show that this enzyme, which is highly expressed in brain, is an IMP-
stimulated glucose1,6-P phosphatase [17]. PMM2 catalyzes the
conversion of Mannose-6-P (Man-6-P) into Mannose-1-P (Man-1-P)
and it is the ﬁrst committed step in synthesis of the activatedmannose
donors GDP-mannose and dolichol-P-Mannose, as shown in Fig. 1.
Synthesis of N-glycans, O-mannose linked glycans, glycophosphoti-
dylinositol anchors, and C-mannosylated proteins all require these
donors. Cells transport exogenous mannose and convert it to Man-6-P
using hexokinase. Alternatively, Man-6-P is formed from Fructose-6-P
using phosphomannose isomerase (PMI or MPI). Both exogenous
glucose and glycogen-derived glucose can contribute to this pathway
[18,19]. The majority of mannose in N-glycans is derived from glucose
in most cells (Freeze and Sharma, unpublished observations).
Deﬁciencies in PMM2 and MPI reduce the amount of Man-1-P and
Man-6-P [20,21], respectively, that are available for glycosylation,
resulting in unoccupied N-linked glycosylation sites on a number of
Fig. 1. Mannose-related metabolic pathways in glycan synthesis. PMM2 deﬁciency, the
cause of CDG-Ia, affects the ﬁrst committed step required for the synthesis of
mannosylated glycans. Reduced production of Man-1-P reduces its ﬂux through the
pathway and leads to reduced N-glycosylation. Whether other pathways are affected is
not known. The goal of therapy is to increase the amount of Man-1-P available for
glycosylation. This can be done by providingMan-1-P directly or by increasing the ﬂuxof
Man-6-P to Man-1-P. Providing normal PMM2, stabilizing or activating the endogenous
enzyme or drivingmoreMan-6-P into the pathwaymay increase the amount ofMan-1-P
and improve impaired glycosylation. See text for a detailed discussion.
Fig. 2. Summary of potential approaches for treating PMM2-deﬁcient patients.
Therapeutic options include replacement of the gene, PMM2, supplementation with
normal enzyme PMM2, or altering the stability or activity of the mutant enzyme. In
addition, the substrate (Man-1-P) can be enhanced bydirect replacement or alterations of
themetabolicﬂux into theglycosylationpathways. Theseoptions are discussed in the text.
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pathology seen in these patients. Excess Man-6-P derived from
mannose is catabolized beginning with PMI. All of the biosynthetic
reactions are thought to occur in the cytoplasm or on the cytoplasmic
face of the endoplasmic reticulum.
3. Setting the stage for therapy: what is possible and practical?
Cellular, genetic, and metabolic options should be considered to
treat PMM2-deﬁcient patients. Some are more practical than others
and/or may be achievable within a reasonable timeframe; but all have
shortcomings. See Table 1 and Fig. 2 for an overview and summary.
Applications of stem cell therapy are in the far future [22]. While they
may hold promise for treating inherited liver disorders [23,24] or
those disorders amenable to hematopoietic stem cell replacement
[25,26] treating systemic glycosylation disorders would be consider-
ably more difﬁcult because of the ubiquitous and cell-autonomous
nature of protein glycosylation. This approach will not be considered
here in favor of near term options and better targets. The goal of
therapy for PMM2-deﬁcient patients is to increase the ﬂux ofTable 1
Therapeutic approaches for PMM2-deﬁcient patients.
Approach Rationale Advantages
Enzyme
replacement
Provides normal active enzyme Corrects defect in cells
sufﬁcient enzyme
PMM2 gene
therapy
Corrects defect by providing DNA encoding
normal enzyme
Permanently corrects d
and integrate DNA
PMM2 enzyme
enhancement
Competitive inhibitor stabilizes mutated
enzyme, but dissociates at lower pH to allow
substrate binding
Small molecule may cr
effective in some lysos
PMM2 activation Non-competitive small molecule activates or
stabilizes mutant enzyme increasing activity
Likely to cross BBB, ma
various ways
MPI inhibition Increase Man-6-P ﬂux toward glycosylation by
reducing MPI activity increasing PMM2:MPI
Small molecule likely
addition of mannose t
severe MPI deﬁciency
AICAR Activate glycogen phosphorylase, driving
glucose→ fructose-6-P and increase Man-6-P
Orally active drug mim
mobilizes glycogenmetabolic precursors into the impoverished glycosylation pathways.
Options include: increase the activity of PMM2, provide Man-1-P
directly, increase theMan-6-P pool and/or redirect this substrate from
glycolysis to glycosylation. Enzyme activity could be increased by gene
therapy that included stem cells, but it is also unlikely to be useful in
the near future, given the inherent risks and very small patient
population [22]. Enzyme replacement therapy has not been tried and
insulin is the only reported activator of PMM2 [27]. Man-1-P is not
membrane permeable, but hydrophobic derivatives can enter cells
and correct impaired glycosylation. However, these compounds tend
to be unstable and toxic. Increasing exogenous mannose can improve
[3H] mannose incorporation in PMM2-deﬁcient cells, but mannose
therapy was not effective in patients.
4. Mannose supplements: simple but ineffective
MPI-deﬁcient patients (CDG-Ib) beneﬁt from alimentary addition
of 300–750 mg/kg/day Man [2,28,29] because it bypasses the
defective step by allowing formation of Man-6-P via hexokinase
(Fig. 1). These children fail to thrive, have coagulopathies, protein-
losing enteropathy and liver ﬁbrosis, and they show remarkable
improvement when the therapy is initiated [28,29]. Fortunately, there
are no neuronal pathologies in this disorder. Possibly mannose in
mother's plasma provides an “endogenous therapy” during fetal life.
In contrast, mannose treatment in PMM2-deﬁcient CDG-Ia
patients was not successful. There was no measurable improvement
in any clinical parameters in children during treatment [30,31] nor
was serum hypoglycosylation decreased. The original basis for
suggesting the treatment was that PMM2-deﬁcient ﬁbroblasts
synthesize a truncated LLO glycan, which becomes normal when
cells are incubated with high concentrations of mannose [32]. TheDisadvantages
that take up and localize Unequal accessibility to cells, especially CNS;
would not cross blood brain barrier, requires
cytoplasmic targeting; high cost
efect in cells that take up Variable accessibility to all cells, especially CNS,
potential tumor formation, safety and regulatory hurdles,
small number of patients
oss blood brain barrier;
omal storage disorders
pH does not change between site of synthesis and action;
substrate competes with inhibitor
y stabilize/activate in May not be useful for all mutant genotypes; will depend
on whether speciﬁc mutation affects enzyme stability,
Km, substrate binding or transcription
to cross BBB activity;
o the diet rescues even
May not be effective in all tissues; likely to beneﬁt those
with higher residual activity.
ics effects of insulin and Studies only done on cell containing 0.5 mM glucose.
Application to physiological conditions unknown
837H.H. Freeze / Biochimica et Biophysica Acta 1792 (2009) 835–840most likely explanation for the failure of mannose therapy in the
patients was that Man-6-P resulting from increased mannose was not
available because it was simply catabolized via MPI, since its activity
remains normal in PMM2-deﬁcient patients.
Another explanation for the failure of mannose therapy in these
patients was suggested based on observations using streptolysin
O-permeabilized cells [33,34]. These studies showed that addition of
Man-6-P to cells preferentially reduced the amount of the major LLO
species, Glc3Man9GlcNAc2-PP-Dol resulting in the liberation of the free
glycan. Thus, increasing Man-6-P in either PMM or MPI deﬁcient cells
could potentially decrease the amount of available LLO and actually
exacerbate deﬁcient glycosylation. However, providing mannose to
either PMM2- or MPI-deﬁcient cells increases the deﬁcient GDP-
Mannose pools [35], showing that the metabolic ﬂux increased, but it
did not increase either the Mannose-6-P pool or decrease cellular
glycosylation [36]. In contrast, providing mannose to intact Mpi-null
mouse ﬁbroblasts greatly increases Man-6-P pools and eventually
depletes ATP stores, since there is no metabolic exit for Man-6-P after
saturating the glycosylation pathway [37]. Increased Man-6-P in Mpi-
null cells decreased the amount Glc3Man9GlcNAc2-PP-Dol LLO, but it
did not appear to affect the amount of protein glycosylation [36]. This
suggests that the amount of LLO is in excess. Changes in steady state
level do not necessarily reﬂect the amount of ﬂux through the
pathway. It is important to distinguish between these.
5. Bypass the defect: membrane permeable mannose-1-P
Another potential approach is to provide Man-1-P directly to cells.
However, Man-1-P does not diffuse, and is not transported across the
cell membrane. To overcome this issue, several groups attempted to
chemically synthesize cell permeableMan-1-P compounds that would
be converted to free Man-1-P after entering the cell, i.e., prodrugs
[38,39]. A series of compounds have been reported [38–40]. One set
showed some biological activity [38]. Man-1-P can be made
membrane permeable by covering phosphates with acetoxymethyl
groups and protecting the OH-groups with ethylcarbonate or acetyl
esters [38]. In cell culture, these compounds correct the LLO
phenotype in several glycosylation-deﬁcient ﬁbroblasts at a lower
concentration thanMan, and also compete with radiolabeled Man in a
glycosylation assay in cells [38]. The study also showed that the level
of GDP-Man increased in response to the compounds. This validates
the theoretical concept. However, all compounds synthesized to date
are far too unstable to be clinically useful. The best compound has a
half-life in serum of about 2.5 min. This is further confounded by the
relatively high concentrations needed to get sufﬁcient diffusion
through the cell membrane. The best compounds must be added to
the medium at a high concentration of around 100 μM to be effective.
The third issue is the toxicity of these compounds. The most effective
compound synthesized so far shows negative effects on protein
synthesis and cell viability at concentrations above 100 μM, i.e. in the
same range as its therapeutic dosage. In a more recent study [40],
Man-1-P pro-drugs containing an additional phosphodiester-linked
mannose residue along with a benzyl or phenyl group on the
phosphate were reported to generate intracellular Man-1-P based
on their ability to compete with 3H-mannose for glycosylation. The
compounds were also reported to have minimal toxicity after 16 h
based on release of lactate dehydrogenase (cell lysis). Additional
studies are needed to conﬁrm and extend these observations. Using
less toxic blocking groups, or lipid carriers [41] for delivery of free
Man-1-P is another. Apart from the labor-intensive synthesis of
making a stable, non-toxic and well-transported compound, no
animal study system is currently available. All PMM2-deﬁcient
patients have some residual enzymatic activity, but complete
elimination of Pmm2 in mice is lethal in early embryogenesis [14].
This is also true for the Mpi-null mouse [37]. Model systems with
quantiﬁable phenotypes will be needed to assess any therapy.6. Enzyme replacement therapy
Enzyme replacement therapy might be possible for PMM2-
deﬁcient patients. This approach has worked well for patients with
lysosomal storage diseases. Gaucher's patients who are deﬁcient in
glucocerebrosidase are treated with Cerezyme® a form of the
expressed enzyme carrying Mannose-terminated N-glycan chains
that targets the enzyme to macrophage in the liver, spleen, and
skeleton where the undegraded glucosecerebroside (Glcβ-Cer) accu-
mulates [42–44]. The enzyme gradually reduces the accumulation of
the substrate since it is trafﬁcked to its normal site of action in the
lysosome [42–44]. Enzyme replacement therapy has also been
approved for other lysosomal storage disorders including Pompe
Disease (α-glucosidase deﬁciency) and MPS1 (α-iduronidase deﬁ-
ciency). Many of these patients have very low residual enzymatic
activity (a few percent) and even slight increases of activity within the
lysosome may be sufﬁcient to improve patients' symptoms gradually
as the accumulated substrate decreases. This may not true for PMM2-
deﬁcient patients where slight increases in activity might still be
within the classical pathological range. Moreover, targeting PMM2 to
the lysosome is not desirable, since it would likely be degraded; it
needs to remain in the cytoplasm.
Many studies show that coupling arginine-rich peptides to high
molecular mass cargos delivers them into cells, through an uptake
system that probably involves multiple receptors, [45] and this has
proven to work in rodents in vivo [46]. Whether sufﬁcient PMM2
could enter cells and reside in the cytoplasmwith an attached cationic
sequence is not known. A slightly modiﬁed approach may offer
another opportunity by binding cationic-derivitized molecules to
heparan sulfate on the cell surface [47]. By converting all ammonium
groups of the antibiotic neomycin to guanidinium groups, molecules
N300 kDa could cross cell membranes at nanomolar transporter
concentrations with delivery being entirely dependent on cell surface
heparan sulfate proteoglycans. By conjugating the guanidinoneomycin
to the ribosome-inactivating toxin, saporin, the study showed
proteoglycan-dependent delivery of cargo into the cytoplasm. Cou-
pling of typical arginine-rich peptides showed both heparan sulfate-
dependent and -independent cellular uptake [47]. Since cell surface
heparan sulfate is nearly ubiquitous, this presents an opportunity to
deliver PMM2 to these cells.
The disadvantage of enzyme replacement therapy is the limited
amount of enzyme that can be delivered to a cell/tissue. Another is
that the enzymes are unlikely to cross the blood brain barrier
providing limited beneﬁt for brain and central nervous system
pathologies.
7. Activate or stabilize PMM2
The only reported activator of PMM2 is an insulin-dependent 2-
fold increase in PMM2 activity seen in Cos7 cells over expressing the
enzyme. Transcription does not increase. Rather, it seems to involve a
serum and glucocorticoid-regulated kinase (Sgk1), which regulates
channels and transporters including the renal epithelial Na(+)
channel (ENaC) [48]. In vitro phosphorylation of PMM2 by this kinase
completely eliminates activity both in the absence and in the presence
of insulin. The interaction with PMM2 was observed in a yeast two-
hybrid screen using Sgk1 as bait, and was conﬁrmed by co-
immunoprecipitation and Sgk1-dependent in vitro phosphorylation
of PMM2. These data suggest that Sgk1 may affect glycosylation, but
the physiological relationship is not clear.
There are no small molecule activators of PMM2, but the
availability of large chemical libraries and robotic high throughput
screening facilities offers a robust opportunity to explore this avenue.
The simple coupled enzymatic assay using MPI, phosphoglucose
isomerase and glucose-6-P dehydrogenase can be easily adapted for
compound screening. Initial leads and structural optimization of
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further reﬁne and optimize the structure activity relationships of
activators. The structure of PMM2 has not been solved, but the
structure of its homolog, PMM1, was determined by X-ray crystal-
lography [49]. The structure suggested a likely, but complex, reaction
mechanism involving cap and core domains, which open to bind
substrate and then close to provide a solvent-exclusive environment
for catalysis. The substrate ﬁrst binds to the cap and then is swept into
the active sitewhen the cap closes. Repulsion of positive charges at the
interface of the cap and core domains stabilizes alpha-PMM1 in the
open conformation, but negatively charged substrate binds to the cap,
thereby facilitating its closure over the core domain. A potential
allosteric or conformational-dependent activator could be tested
initially using normal PMM2, but its activity must also be conﬁrmed
on PMM2 carrying several common mutations to select the com-
pounds with broadest application. A small molecule could potentially
pass the blood brain barrier. A disadvantage of the approach is the
possibility that effective inhibitors are more effective on some mutant
forms than on others, which may limit their general application.
Enzyme enhancement therapy has shown some success in treating
lysosomal storage disorders [42,43]. This approach exploits the well-
known fact that substrates or their analogs stabilize enzymes.
Competitive inhibitors bind at or near the active site of the mutated
enzymes at neutral pH and are then released at low pH when the
enzyme arrives in the lysosome. Thesemolecules may only marginally
increase the residual activity up to a few percent of normal, but this is
sufﬁcient to reduce the ongoing accumulation of non-degraded
substrates. A competitive inhibitor is probably not useful for PMM2
because its synthesis and continued residence in the cytoplasm
precludes a pH-dependant inhibitor dissociation to allow substrate
binding. Identiﬁcation of an allosteric activator, as described above,
has a greater chance of success. Recently, a combination of protein
speciﬁc pharmacologic chaperones and induction of the protein
folding machinery synergized to allow mutated proteins to survive
within the secretory pathway [50]. This approach may hold promise
for ER or Golgi associated proteins that are mutated in other types of
glycosylation disorders, but similar approach for PMM2would require
its stabilization and dampening of cytoplasmic protein degradation.
8. Increase mannose-6-P ﬂux into glycosylation pathways
It should be possible to encourage the ﬂux of Man-6-P toward the
glycosylation pathways in PMM2-deﬁcient cells. Metabolic labelingFig. 3. Metabolism of [2-3H] mannose: the metabolic fate of exogenous mannose. Thwith [3H] Mannose showed that these cells synthesize truncated LLO
species and transfer them to proteins [32]. Addition of 250–500 μM
mannose to the culture medium, normalizes both the LLO pattern and
the size of protein-bound glycans. Hyperphysiological (severe
diabetic) concentrations of glucose (N10 mM) also corrected the
size, but clearly mannose was N20 fold more effective [32]. Since
mannose is well tolerated at 4–5× the normal plasma concentration of
50 μM, it would be reasonable to increase plasma mannose
concentration. As mentioned above, mannose is not effective in
PMM2-deﬁcient patients, most likely because MPI is fully active and
consumes the Man-6-P. The unfavorable ratio of PMM2:MPI activity
does not favor glycosylation. Increasing mannose delivery to the cells
either by increasing extracellular mannose concentration or by
improving its delivery into the cells might improve this situation.
The antidiabetic drug, metformin, which stimulates the AMP-
activated protein kinase, was reported to provide a preferential 2-
fold stimulus of mannose uptake into ﬁbroblasts [51]. However, this
stimulation is not seen at normal plasma glucose concentration
(5 mM), so it is unlikely to increase mannose delivery in normal
conditions. Another way to increase Man-6-P is by increasing the ﬂux
of glucose into fructose-6-P via glycolysis. One study showed that 5-
aminoimidazole-4-carboxamide riboside (AICAR), which activates
glycogen phosphorylase and suppresses glucose-6-phosphatase tran-
scription [52] can provide mannose for glycan synthesis [34,53]. Other
studies also show that glycogen is a source of mannose in the plasma
[19] AICAR was found to prevent fat accumulation in sedentary mice
and was suggested as a way to increase endurance without exercise
[54]. PMM2-deﬁcient patients have normal plasma glucose and
apparently normal glycogen stores. For unexplained reasons, they
usually show a severe failure to thrive as infants, and as children, they
struggle to gain weight, and are sometimes fed through gastrostomy
tubes. Use of AICAR as a way to increase intracellular Man-6-P in
PMM2-deﬁcient patients would require caution.
An approach, which we have pursued, hinges on the observation
that the amount of exogenous mannose directed toward glycan
synthesis (PMM2-dependent) vs. catabolism (MPI-dependent) is
determined by the ratio of PMM2:MPI. Higher PMM2 activity, and
lowerMPI activity, drivesmoreMan-6-P into the glycosylationpathway.
Combining MPI inhibitors with hyper-physiological concentrations
of mannose may increase Man-6-P ﬂux in favor of glycosylation.
MPI is a zinc-dependent enzyme and so typical chelators such as
1,10-phenathroline, EDTA and 2,2′-dipyridyl are effective inhibitors
[55,56]. Competitive inhibitors include phosphorylated analogs suchis versatile radiolabel is the best indicator of mannose ﬂux into these pathways.
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these is speciﬁc or membrane-permeable. Fructose-1-P was reported
to inhibit MPI and this was offered as an explanation why patients
with uncontrolled hereditary fructose intolerance make hypoglyco-
sylated proteins [57]. Previous screening of a combinatorial chemical
library identiﬁed amembrane permeable compound, but its biological
effects were uncharacterized [58]. The crystal structure of Candida
albicansMPI is known [59], and software programs canmodel docking
of substrate and/or potential competitors.
We used high throughput screening of chemical libraries to
identify a ﬁrst generation of MPI inhibitors [60]. The traditional
MPI-coupled enzyme assay leading to NADPH+ formation was used,
along with counter screens to eliminate effects on the coupling
enzymes (phosphoglucose isomerase and G6PD) which are required
for production of NADPH+ [55]. After identifying possible inhibitors,
dose–response, and IC50 values for either competitive or (preferably)
non-competitive inhibitors were done using the coupled assays.
Direct in vitro conﬁrmation is easy using only MPI, based on formation
of 3HOH from [2-3H]Man-6-P (Fig. 3) and expressed enzyme
[28,37,61]. This simple assay can be directly applied to cells to assess
the biological effectiveness of compounds by comparing the ratio of
[2-3H]mannose incorporation into glycans (TCA precipitate) vs. 3HOH
production. The inhibitor should increase the incorporation of label
into glycans and decrease the amount of 3HOH produced. This method
can be used to assess the effects of inhibitors in more complex models
such as mice or zebraﬁsh. Previous studies using mice and most cell
lines show that the great majority of [2-3H] mannose is catabolized via
MPI, with production of 3HOH ([61,62]; and unpublished observa-
tions). Increased organ speciﬁc incorporation of label into glycans
would indicate that the MPI-speciﬁc inhibitors have been effective at
that location. An inhibitor should decrease the amount or rate of 3HOH
appearance in the plasma, but the organ/tissue that produced it could
not be determined.
We screened ∼200,000 compounds and identiﬁed a series of
compounds with IC50's in the range of 1–5 μM. Tests on amultiple cell
lines showed that, only a few of these increased [2-3H] mannose
incorporation into proteins and lowered formation of 3HOH. The
increased incorporation is consistent with about a 70% reduction MPI
activity. Commercially available and custom-synthesized analogs are
being interrogated in order to increase the efﬁciency of inhibition.
Such inhibitors have limitations. Besides the obvious caveats of off-
target effects, toxicity, and short half life, inhibitors may have limited
access to some tissues or only be effective in selected tissues where
the normal ratio of PMM2:MPI is favorable. For instance in the mouse,
the MPI speciﬁc activity in liver was measured at about 15 nmol/min/
mg protein, but it is nearly 60 nmol/min/mg in the heart and
∼120 nmol/min/mg in testis. It may be more challenging to reduce
MPI activity sufﬁciently to drive the elevated plasmamannose into the
glycosylation pathway in these tissues with high MPI activity.
9. Future perspectives and challenges
Individual or combinations of PMM2 activators, MPI inhibitors
+plasma mannose, and PMM2 replacement may offer hope to
improve glycosylation in some PMM2-deﬁcient patients. Small
molecules may traverse the blood brain barrier, but PMM2 will not.
On the other hand, the half-life of PMM2 may be signiﬁcantly longer
than that of either inhibitors or activators. Differential accessibilities of
small molecules and PMM2 are signiﬁcant hurdles to overcome. Since
PMM2-deﬁciency affects so many organ systems in acute, chronic, and
progressive ways, it is worthwhile to consider simultaneous explora-
tion of all these approaches. It is difﬁcult to predict which aspects of
PMM2-deﬁcient patients' phenotype would respond to therapy.
The major limitation on development of these therapies is the lack
of appropriate model systems, since the knockout mouse is lethal [14].
It is unlikely that organ- or temporal-speciﬁc knockout expression,e.g., ﬂoxed alleles, could be generally useful, but this would depend on
the organ-to-organ variability in excision efﬁciency. Moreover, each
cell is responsible for generation of its own Man-1-P and elimination
of all PMM2 activity would preclude analysis of Pmm2 activators or
Mpi inhibitors. Knock-in of human disease-causing PMM2 mutations
may offer hope, although animals with observable phenotypes must
be generated while avoiding embryonic or early post-natal lethality. A
construct that allowed temporal or organ-speciﬁc elimination of the
normal allele and simultaneous expression of the selected mutation
might provide a useful model. Another approach might be to identify
PMM2 shRNAi molecules that give 80–90% reduced enzymatic activity
and stably integrate them into 2–4 cell embryos via lentiviral
constructs [63]. This procedure could yield individuals for phenotypic
analysis, but these viral constructs frequently integrate into multiple
sites on different chromosomes [63], which would complicate the
creation of a stable knockdown line. Nevertheless, such experiments
may provide information on a range of phenotypic abnormalities in a
series of individual mice. Zebraﬁsh present another opportunity to
test the therapeutic agents since the morpholino mutants produce
hypomorphic alleles, similar to patients [64,65]. This system offers
great promise. A non-genetic approach to generate a PMM2-deﬁcient
model system would be to identify a speciﬁc inhibitor of PMM2. This
could easily be done in the same high throughput screen searching for
a therapeutic PMM2 activator. A rather different approach would be to
reduce the impact of hypoglycosylation of key proteins as suggested
by Shang et al. [66]. They propose that tailoring the rate of protein
synthesis to impaired ﬂux through the glycosylation pathway might
be useful.
10. Conclusions
In the last decadewe havemade great progress in identifying a few
dozen human glycosylation disorders [2,4]. We have made almost no
progress in providing the patients and families with potential
therapies. The advent of high throughput compound screening offers
a new avenue for development of therapies targeting the N-
glycosylation pathway. The technology provides tools and reasonable
approaches to assess the efﬁcacy of potential lead compounds. Robust
PMM2 deﬁciency models are needed to test these concepts and
molecules before they will lead to useful products. International
cooperation and collaboration among scientists are essential if we are
to do “the right thing” and offer children and families evidence of our
uniﬁed hopes for their future.
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